Slide

Welcome

This is MU-JHU!

We are an indigenous medical research and care organization in existence since 1988, located on Upper Mulago Hill in Kampala. MU-JHU is a key player in contributor to new knowledge in HIV prevention, care, and treatment, community HIV programs as well as non-HIV research, and training. We envision a Uganda where all women, children, adolescents, and their families enjoy full health and wellbeing. Our mission is to be a Centre of excellence in health research, and care for women, adolescents, children, and their families.

About Us

Our Mission

To undertake health research, provide health-services and conduct training; focusing on HIV, prevalent and emerging conditions affecting the well-being of women, children, youth and families.

Research

Programs

Community

Our Research Domains

Perinatal HIV/TB Prevention and Care
Pediatric and Infant Health
Growth, Neurodevelopment and Bone Health
Bacterial Infections and Vaccine Development
Blood Safety and Infection Prevention

Clinical Trial Phases

Phase I (Safety & Dosage)
Phase II (Effectiveness & Side Effects)
Phase III (Efficacy & Comparison)
Phase IV (Long-term/Post-marketing)
Adaptive Trials

See Clinical Research Regulations in Uganda

Learn more

Announcements

Scholarships

Call For Applications

D43 Paediatric Modular Training Program

Medium-Term Practicum Training for Nurse Study Coordinators

New Studies

Our latest protocols and clinical trials

An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase: NeoSep1. Principal Investigator – Dr. Maxensia Owor
IMPAACT 2024: Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. Principal Investigator – Dr. Eric Wobudeya
A phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB). Principal Investigator – Dr. Deo Wabwire
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. Principal Investigator – Dr. Flavia Matovu Kiweewa

New Articles

Baseline adverse birth outcomes in a prospective pregnancy cohort in Uganda: Evidence to inform maternal vaccine readiness Hospitalization Rates and Associated Factors Among Older Adults With HIV in the United States

August 2026

View all Publications

Hospitalization Rates and Associated Factors Among Older Adults With HIV in the United States

July 2026

View all Publications

HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial

13th June 2026

View all Publications

Our Work